부산대학교 도서관

BAY o 9867, a new antibacterial agent of quinoline carboxylic acid group synthesized by BAYER AG, West Germany, was examined on its antibacterial activity in vitro, as well as on its clinical usefulness. The results obtained were as follows:1. Antibacterial activity in vitro: MICs of BAY o 9867 against bacterial strains of S. aureus, K. pneumoniae, E. coli, S. marcescens, P.aeruginosa and of Proteus species isolated from clinical infection foci were compared with those of other agents of pyridone carboxylic acid group, i. e. Ofloxacin, Enoxacin and Norfloxacin, as well as with those of some antibiotics, i. e. Cephalexin, Cefaclor and Ampicillin. BAY o 9867 showed distinctively higher activity against all species of gram-negative bacilli examined than any other synthesized agents and antibiotics tested. The drug was also highly active against S. aureus strains, too, similarly to Ofloxacin.2. Clinical trials: Thirty-three cases of various infections were treated with BAY o 9867 100-400 mg×1-3/day for 1-14 days. In four of the patients, the evaluation of effectiveness of the therapy was impossible.Out of the remaining twenty-nine cases (RTI 20, UTI 3 and Enterocolitis 6), twenty-one well responded to the therapy (efficacy rate: 72.4%). As to the untoward reactions to the drug detected among the total thirty-three cases, two complained of dizziness, and three of abdominal indisposition. Laboratory examinations, hematological and chemical, carried out in twenty-one of the patients, revealed only slight elevation of S-GOT and S-GPT in two of them.These results obtained suggest the clinical usefulness of BAY o 9867 as a new antibacterial agent.